All Online

1 - 9 of 9 results

Refine

Active filters

GLP-1 Receptor Agonists
0.52 CME CREDIT

1 CME CREDIT

This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines.


1 CME CREDIT

This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 7, 2020, and they are subject to change as new information is published.


0.51 CME CREDIT

An Interactive Webcast: A Deeper Dive into T2DM Treatment

0.50 CME/MOC
0.51 AANP | 0.22 Pharmacology


0.52 CME CREDIT

An Interactive Webcast: Initiating and Managing Insulin

0.50 CME/MOC
0.52 AANP | 0.20 Pharmacology


0.75 CME CREDIT

Two leading experts in type 2 diabetes management will review the benefits and limitations of GLP-1 receptor agonists, including a new oral agent in this class, by providing expert syntheses of clinical trial data and demonstrating how to turn this information into useful, actionable guidance for routine patient care.


1 CME CREDIT

Adults with type 2 diabetes mellitus (T2DM) have a two- to four-fold increase in risk for cardiovascular (CV) morbidity and mortality. This session cuts to the heart of primary and secondary prevention in this population, presenting recent data on antihyperglycemic medications with proven cardiovascular benefit in the context of updated management algorithms. Individualized treatment is critical to the success of these treatment plans. The faculty will help you optimize adherence through shared decision-making tactics that account for CV risk factors, comorbidities, and patient preferences. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/26/2020, and they are subject to change as new information is published.


0.5 CME CREDIT

Join Dr. Sanjiv Chopra, hepatologist, author, speaker, and thought leader as he interviews his guest, Dr. Martin Abrahamson, endocrinologist and associate professor at Harvard Medical School as they discuss major advances in diabetes as well as the promise of stem cell treatment, diet and weight loss in patients with diabetes, and advances in continuous glucose monitoring. The pair will end their conversation discussing what they have learned from patients over the years.